Replies to post #115132 on Biotech Values

[mcbio]

Is it valuation? Is it the fact that Ponatinib results are still 12-15 months away (at least)? Do you not like what you see with the Ridaforolimus compound? There's got to be a reason. I'm just wondering what it is...

I certainly like what I see in ponatinib. But, given that rida is in front of it and I still have a few questions/concerns, I'm not ready to pull the trigger on ARIA as I think there's a chance that any negative rida news (lack of OS benefit in sarcoma namely and/or MRK ultimately disclosing that they're not going to file for approval in sarcoma) could drive ARIA lower and create an even better buying opportunity. So, I'm willing to wait.